Oral Roflumilast in Lichen Planus: A Prospective Real‐World Case Series of Ten Adults
Australasian Journal of Dermatology · 2026-11 · 67 (7)
DOI: 10.1111/ajd.70198 ↗Kurz gefasst
Fachartikel in der Zeitschrift Australasian Journal of Dermatology, online erschienen am 18.08.2026. Verfasst von Francisco José Navarro-Triviño und 4 weiteren Autor:innen. Beteiligte Einrichtung: Immunoallergic Diseases Unit, Dermatology Department, Hospital Universitario San Cecilio, Granada, Spain. Hauptthemen laut MEDLINE: Aminopyridines, Phosphodiesterase 4 Inhibitors, Benzamides, Lichen Planus. Die Arbeit nennt 16 Literaturangaben.
Abstract (Originalsprache)
Lichen planus (LP) is a chronic inflammatory dermatosis with limited systemic treatment options, and prospective data on oral phosphodiesterase‐4 (PDE4) inhibition are lacking. We conducted a prospective real‐world case series of ten adults with clinically and/or histologically confirmed LP treated with oral roflumilast, assessing disease severity using the Investigator's Global Assessment (IGA), pruritus and sleep disturbance using Numeric Rating Scales (NRS) and quality of life using the Dermatology Life Quality Index (DLQI). At baseline, 90% of patients presented moderate‐to‐severe disease (IGA 3–4). By week 12, 7 of 9 evaluable patients (78%) achieved IGA 0–1, increasing to 6 of 7 evaluable patients (86%) at week 24. Mean pruritus NRS improved from 7.7 to 1.6, sleep disturbance NRS from 7.3 to 2.0 and DLQI from 12.0 to 3.6. Overall, eight patients (80%) achieved at least 75% clinical improvement and six (60%) complete remission. The most frequent adverse events were insomnia (50%) and loose stools (30%), and two patients (20%) discontinued treatment because of adverse events. These preliminary prospective real‐world findings suggest that oral roflumilast may represent a potential therapeutic option for LP and support further controlled studies to define the role of PDE4 inhibition and optimal dosing in this condition.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Immunoallergic Diseases Unit, Dermatology Department, Hospital Universitario San Cecilio, Granada, Spain.
- Dermatology Department, Hospital Universitario San Cecilio, Granada, Spain.
- Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain.
- Autoimmune Diseases Unit, Department of Dermatology, Hospital Universitario San Cecilio, Granada, Spain.
- Psoriasis Unit, Department of Dermatology, Hospital Universitario San Cecilio, Granada, Spain.
- Trichology Unit, Department of Dermatology, Hospital Universitario San Cecilio, Granada, Spain.
ORCID-Profile: Francisco José Navarro-Triviño, David Moyano-Bueno, José María Llamas-Molina, Ricardo Ruiz-Villaverde, Francisco Javier de la Torre-Gomar
Zitieren
APA
Navarro-Triviño, F. J., Moyano-Bueno, D., Llamas-Molina, J. M., Ruiz-Villaverde, R., & de la Torre-Gomar, F. J. (2026). Oral Roflumilast in Lichen Planus: A Prospective Real‐World Case Series of Ten Adults. Australasian Journal of Dermatology, 67(7). https://doi.org/10.1111/ajd.70198
Vancouver
Navarro-Triviño FJ, Moyano-Bueno D, Llamas-Molina JM, Ruiz-Villaverde R, de la Torre-Gomar FJ. Oral Roflumilast in Lichen Planus: A Prospective Real‐World Case Series of Ten Adults. Australasian Journal of Dermatology. 2026;67(7). doi:10.1111/ajd.70198
BibTeX
@article{NavarroTrivio2026,
author = {Navarro-Triviño, Francisco José and Moyano-Bueno, David and Llamas-Molina, José María and Ruiz-Villaverde, Ricardo and de la Torre-Gomar, Francisco Javier},
title = {Oral Roflumilast in Lichen Planus: A Prospective Real‐World Case Series of Ten Adults},
journal = {Australasian Journal of Dermatology},
year = {2026},
volume = {67},
number = {7},
doi = {10.1111/ajd.70198}
}
EUVIMED